TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3914805
Drug: Multiple s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple s.c. injections via butterfly 5-6x daily
Study: 30920278
Drug: Growth-mindset only
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth-mindset only treatment
Study: 23235413
Drug: Transcranial stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial stimulation (TS) along with standard treatment (antiaggregant vascular drugs and hypocaloric diet)
Study: 14734454
Drug: Large multivalent
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large multivalent immunogen (LMI) administered without adjuvant, one-half intradermally (i.d.) and the other half subcutaneously (s.c.) at doses of 10-, 30-, or 100-million tumor cell equivalents on weeks 0, 4, and 8.
Study: 14625516
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein supplement 0.5 g/kg body mass/day
Study: 10668490
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (3 gm daily; 1200 mg elemental calcium)
Study: 1712206
Drug: L-deprenyl (LD)
Normalized name: L-deprenyl-D2 C-11
DrugBank: L-deprenyl-D2 C-11 (DB12650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-deprenyl (LD)
Study: 2871818
Drug: Molsidomine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (2 mg)
Study: 2871818
Drug: Risordan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risordan (20 mg)
Study: 2871818
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release Trinitrin (2.5 mg)
Study: 2871818
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release Trinitrin (5 mg)
Study: 2871818
Drug: Lenitral (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenitral (7.5 mg)
Study: 2871818
Drug: Langoran (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Langoran (40 mg)
Study: 2871818
Drug: Trinitrin skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trinitrin skin patch (10 mg)
Study: 26719492
Drug: Equal preference
Normalized name: equol, (+-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equal preference among biologics for themselves (aflibercept 30.6%, bevacizumab 36.5%, ranibizumab 32.9%)
Study: 16885120
Drug: Procaterol HCl
Normalized name: procaterol HCl
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol HCl pellets capsule
Study: 10950051
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg budesonide
Study: 1362137
Drug: Alpidem (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpidem (75 to 150 mg daily, 25-50 mg t.i.d. for 3 weeks)
Study: 24686825
Drug: Triadic gaze
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triadic gaze (TG) treatment twice weekly with a speech‐language pathologist for 29 sessions over 17 weeks
Study: 23118850
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy Group (CBT)
Study: 20880642
Drug: Natural menopausal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural menopausal supplements and diets rich in isoflavones
Study: 20880642
Drug: Paroxetine, fluoxetine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine, fluoxetine, bupropion
Study: 18035078
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) (48 hours)
Study: 16192448
Drug: 30-microg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-microg dose of technetium-99m-labeled monodisperse albuterol aerosols with particle sizes of 1.5 microm, 3 microm, and 6 microm
Study: 16192448
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg metered-dose inhaler (MDI) albuterol
Study: 12270622
Drug: Moulded isomalt-based
Normalized name: Isomalt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moulded isomalt-based tablet (50 mg HCT)
Study: 12270622
Drug: Moulded isomalt-based
Normalized name: Isomalt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moulded isomalt-based lozenge (50 mg HCT)
Study: 12270622
Drug: Conventional tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tablet (Dichlotride 50 mg)
Study: 7637152
Drug: Bupivacaine-fentanyl continuous
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bupivacaine-fentanyl continuous infusion (BF-C group)
Study: 7637152
Drug: Morphine bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine bolus injection (M-S group)
Study: 2474109
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 mg initially, adjusted between 1.25-20 mg)
Study: 2474109
Drug: Ramipril plus
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril plus HCT (25 mg)
Study: 1158003
Drug: Cream base
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream base alone
Study: 28482144
Drug: Canakinumab treatment
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab treatment
Study: 26447149
Drug: Parenteral Nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral Nutrition
Study: 28364509
Drug: Almorexant 50
Normalized name: Nemorexant
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Almorexant 50 mg
Study: 28364509
Drug: Almorexant 25
Normalized name: Nemorexant
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Almorexant 25 mg
Study: 28364509
Drug: Almorexant (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almorexant (all doses)
Study: 22527308
Drug: Bibrocathol 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bibrocathol 2% eye ointment
Study: 19745175
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day encapsulated fish oil (1.2 g total omega-3: 0.7 g DHA; 0.3 g EPA)
Study: 19745175
Drug: Placebo oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oil (combination palm and soy)
Study: 9626787
Drug: Low-dose leucovorin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose leucovorin (20 mg/m2/day, days 1 through 5) combined with 5-FU (400 mg/m2/day every 4 weeks)
Study: 9626787
Drug: High-dose leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose leucovorin (200 mg/m2/day, days 1 through 5) combined with 5-FU (400 mg/m2/day every 4 weeks)
Study: 9626787
Drug: High-dose leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose leucovorin combined with 5-FU
Study: 3312283
Drug: Micronized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized oral progesterone, 200 mg daily
Study: 29921036
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) and lattice CO2 laser treatments
Study: 29921036
Drug: Conventional approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional approach with scar cream massage and silica gel products
Study: 25135744
Drug: 6 SQ
Normalized name: American house dust mite allergenic extract 6 SQ-HDM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 SQ HDM SLIT-tablet
Study: 20841796
Drug: Email reminders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Email reminders focused on unrelated content (oral cancer prevention)
Study: 18048572
Drug: Oral unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral unfractionated heparin with sodium N‐[8‐(2‐hydroxybenzoyl) amino]caprylate (salcaprozate sodium, SNAC)
Study: 18048572
Drug: Parenterally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenterally administered unfractionated heparin
Study: 18048572
Drug: Oral unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral unfractionated heparin with SNAC
Study: 2223344
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% EMLA cream
Study: 2223344
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream and 1% lignocaine infiltration
Study: 353090
Drug: Anisotropine methyl
Normalized name: Anisotropine methylbromide
DrugBank: Anisotropine methylbromide (DB00517)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anisotropine methyl bromide, 80 mg given orally at 8 P.M.
Study: 30702534
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac potassium (50 mg)
Study: 30702534
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (1 g in 500 ml normal saline over 20 min)
Study: 28826727
Drug: Drug-eluting balloon
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting balloon (DEB) with provisional bare-metal stenting
Study: 28826727
Drug: Primary stenting
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary stenting with drug-eluting stents (DES)
Study: 26764322
Drug: Aged Garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged Garlic Extract (AGE) 2400 mg/d
Study: 21270270
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion on day 2
Study: 16645371
Drug: Inhaled Nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Nitric Oxide (iNO)
Study: 17952474
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without hypnosis
Study: 11703529
Drug: Topical aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical aspirin (75 mg/mL in moisturizer, 5-10 mL, three times a day for 21 days)
Study: 11703529
Drug: Oral aspirin
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aspirin (375-750 mg three times a day for 21 days)
Study: 8005127
Drug: Oral enoximone
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enoximone (100 mg t.i.d.)
Study: 8005127
Drug: Oral enoximone
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enoximone
Study: 2805771
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg trazodone conventional capsules
Study: 2805771
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg controlled‐release tablets
Study: 2805771
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of trazodone
Study: 1103708
Drug: Alprenolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol (200 mg twice daily)
Study: 23880426
Drug: Iopromide 300
Normalized name: IOPROMIDE 300mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide 300 mg/ml with fixed-dose injection protocol
Study: 23880426
Drug: Iopromide 300
Normalized name: IOPROMIDE 300mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide 300 mg/ml with body surface area adapted injection protocol
Study: 23880426
Drug: Iopromide 370
Normalized name: IOPROMIDE 370mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide 370 mg/ml with fixed-dose injection protocol
Study: 23880426
Drug: Iopromide 370
Normalized name: IOPROMIDE 370mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide 370 mg/ml with body surface area adapted injection protocol
Study: 21825259
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg daily orally until disease progression (PD) occurred
Study: 21825259
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with paclitaxel 200 mg/m2 IV and carboplatin AUC 6 IV on day 1 intercalated with erlotinib 150 mg orally on days 2 through 15 every 3 weeks for four cycles followed by erlotinib 150 mg orally until PD occurred
Study: 14614579
Drug: Rifampicin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (600 mg daily for 5 days)
Study: 11303851
Drug: Cefepime (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (50 mg/kg/dose every 8 h; ≤ 6 g/day)
Study: 11303851
Drug: Ceftazidime (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (50 mg/kg/dose every 8 h; ≤ 6 g/day)
Study: 7605521
Drug: Prophylactic systemic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic systemic antibiotics
Study: 3402097
Drug: Non-antibiotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-antibiotic group
Study: 31732485
Drug: Drug-susceptible tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-susceptible tuberculosis
Study: 2526824
Drug: Acitretin 50
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin 50 mg/day
Study: 18276652
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 50 mg kg(‐1) i.v. as a bolus and then 15 mg kg(‐1) h(‐1) i.v. by continuous infusion
Study: 16949484
Drug: Concordant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concordant treatment allocation
Study: 16949484
Drug: Discordant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discordant treatment allocation
Study: 10671664
Drug: FPLC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPLC chemotherapy
Study: 10671664
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no FPLC chemotherapy)
Study: 8445428
Drug: Delayed intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed intensification (Delint) phase of therapy
Study: 8445428
Drug: Standard three-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard three-drug induction and Delint
Study: 8445428
Drug: Intrathecal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal methotrexate (IT MTX) during all phases of therapy
Study: 3731891
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication (group 2)
Study: 26501498
Drug: Cognitive-behavioral conjoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral conjoint therapy (CBCT) for PTSD
Study: 24794367
Drug: Fluconazole (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (6 mg/kg of body weight)
Study: 16739748
Drug: Supplemental external-beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental external-beam radiation therapy (XRT)
Study: 14668071
Drug: Nicotine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (20 microg/kg) administered by nasal spray
Study: 10901307
Drug: Any prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any prophylactic agent
Study: 1519588
Drug: Prednisolone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (50 mg/day) for 1 month
Study: 29629603
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream applied for 30 minutes
Study: 9649697
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream applied for 60 minutes
Study: 25168927
Drug: Prophylactic haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic haloperidol 1 mg twice daily for a maximum of seven consecutive days
Study: 22901557
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (Omacor, 3 g/d) for 6 months
Study: 7308331
Drug: Metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 200 mg in ordinary tablets
Study: 7308331
Drug: Metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 200 mg in slow-release tablets
Study: 7308331
Drug: Terbutaline (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (beta 2-receptor stimulating agent)
Study: 26369489
Drug: salivary substitute
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: salivary substitute as an adjunct to scaling and root planing (SRP)
Study: 24372304
Drug: 3K3A-APC at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3K3A-APC at 6, 30, 90, 180, 360, 540 or 720 µg/kg
Study: 24372304
Drug: 3K3A-APC at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3K3A-APC at 90, 180, 360, or 540 µg/kg
Study: 21392372
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus Manual Lymphatic Drainage
Study: 21392372
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (skin care, exercise, compression measures, bandages for one month, and compression garments)
Study: 19711495
Drug: Culturally tailored
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally tailored cervical cancer education program in three weekly sessions
Study: 21378155
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg daily
Study: 10022641
Drug: Plantago ovata
Normalized name: Plantago ovata seed
DrugBank: Plantago ovata seed (DB14585)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plantago ovata seeds (10 g b.i.d.)
Study: 10022641
Drug: Mesalamine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine (500 mg t.i.d.)
Study: 10022641
Drug: Plantago ovata
Normalized name: Plantago ovata seed
DrugBank: Plantago ovata seed (DB14585)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plantago ovata seeds plus mesalamine (same doses)
Study: 7496561
Drug: Atropine 1
Normalized name: homatropine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 1 mg (antimuscarinic)
Study: 7496561
Drug: Nicergoline 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline 2.5 mg (alpha blocker)
Study: 7496561
Drug: Esmolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 40 mg (beta 1 blocker)
Study: 98127
Drug: Penfluridol, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penfluridol, 20 to 160 mg orally once each week
Study: 98127
Drug: Fluphenazine decanoate,
Normalized name: FluPHENAZine Decanoate, decanoate 25 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluphenazine decanoate, 0.5 to 4 ml every two weeks
Study: 30311042
Drug: L2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L2 treatment (compared to L1 only)
Study: 28361371
Drug: Beta-blocker up-titration
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta-blocker up-titration over 12 weeks
Study: 17989314
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy (IST) - second course
Study: 12882864
Drug: AC2993 (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC2993 (0.08 micro g/kg)
Study: 11077932
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate (177 mg/kg/day in three divided doses equivalent to 40 mg elemental zinc)
Study: 28849265
Drug: Intraoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative chemotherapy
Study: 6209506
Drug: Propranolol, 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 160 mg (single oral dose)
Study: 25318980
Drug: Routine health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine health education offered monthly by health staff at health facilities
Study: 19332196
Drug: High-dose simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose simvastatin (80 mg)
Study: 10335764
Drug: Low-dose simvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose simvastatin (40 mg)
Study: 10335764
Drug: High-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose atorvastatin (40 mg)
Study: 8935744
Drug: Thiamine hydrochloride
Normalized name: Thiamine Hydrochloride
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine hydrochloride (vitamin B1) 100 mg orally, daily for 90 days
Study: 31401973
Drug: 7.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/kg rabbit ATG
Study: 31401973
Drug: 10.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.0 mg/kg rabbit ATG
Study: 22578975
Drug: Easy separation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Easy separation from CPB (no support or one vasoactive agent/inotrope)
Study: 22578975
Drug: Difficult separation
Normalized name: Clostridioides difficile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difficult separation from CPB (two drug types used)
Study: 19507027
Drug: Enteric-coated, delayed-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated, delayed-release peppermint oil (Colpermin)
Study: 760589
Drug: Oral oxazepam
Normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral oxazepam
Study: 25772548
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg as add-on to sulphonylurea
Study: 25772548
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg as add-on to sulphonylurea